ReNeuron Group is engaged in the research, development and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications worldwide. Its lead therapeutic candidate is ReN001 stem cell therapy, which is in clinical development stage for the treatment of patients left disabled by the effects of a stroke. The company also develops ReN009 stem cell therapy to treat peripheral arterial disease; and ReN003 programme for blindness-causing diseases. For further information, visit the company’s Web site at www.reneuron.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: